• Tissue biopsy isn’t the only path forward. FoundationACT provides comprehensive genomic results using only a blood sample, and can have a profound clinical impact. Learn more about Foundation Medicine’s liquid biopsy test …

    Continue Reading

  • Diving Deeper Into Cancer Immunotherapy Biomarkers

    Cancer immunotherapy is transforming the treatment landscape for many types of cancer, but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field. Personalized targeted therapies have traditionally been prescribed based on the presence of single …

    Continue Reading

  • Completing the Puzzle for Colorectal Cancer

    Each person and each cancer is unique, and the goal of precision medicine is to uncover this individuality. For colorectal cancer (CRC), we have discovered a few important pieces of the puzzle, but the entire picture is incomplete. There is an urgent need to discover more specific predictive markers of CRC that can …

    Continue Reading

  • A child getting diagnosed with cancer is devastating and can often be compounded by not knowing how to help, or what to do next. Many pediatric cancers are still not well understood, and it remains the leading cause of death by disease among children in the United States.1 Fortunately, advances in research have …

    Continue Reading

  • Shaping the Future of Liquid Biopsies

    At Foundation Medicine, we firmly believe that precision medicine is the future of cancer care. And if we want to make this future a reality, we need collaboration. Collaboration across multiple partners is essential to realizing the full potential of innovative new technologies that may change the way we identify and …

    Continue Reading

  • The passage of the 21st Century Cures Act on December 7th was a milestone for America’s Precision Medicine initiative. The landmark bill includes $4.8 billion over the coming years for Vice President Biden’s Moonshot Program and, specifically, to advance programs at NIH, NCI and FDA. Further advancing the precision …

    Continue Reading

  • Today, Foundation Medicine introduced FoundationFocus™ CDxBRCA, our first product to be approved by the U.S. Food and Drug Administration (FDA). This companion diagnostic is intended to aid in identifying women with ovarian cancer for whom treatment with Rubraca™ (rucaparib) tablets, a therapy developed by Clovis …

    Continue Reading

  • Lung cancer is a complex disease that carries a cultural stigma and a daunting outlook for the thousands of people who are diagnosed with this disease each year.1 But significant advances in identifying many of the molecular drivers of lung cancer, and genetically pinpointing these drivers within each patient’s tumor, …

    Continue Reading

  • One in eight women in the US will develop breast cancer in their lifetime.1 Many of these women, however, will ultimately add “survivor” to their diagnosis thanks to today’s treatment options. Breast cancer survival has tripled in the last 60 years2, demonstrating just how far we’ve come in fighting a disease that …

    Continue Reading

  • Blood cancers have helped shape the evolution of cancer treatment from the beginning. As early as World War II, the first chemotherapies were developed to help people living with lymphoma.1 Following those early approaches, we’ve experienced a revolution in our understanding of the genomic drivers of hematologic …

    Continue Reading